Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Neil Clendeninn"'
Autor:
Sharon Chapman, R.E. Myers, Pablo Tebas, Neil Clendeninn, Michael Sension, Anderson R, Michael S. Saag, Marcus A. Conant
Publikováno v:
AIDS. 15:1971-1978
Objective: To evaluate the safety and antiretroviral activity of nelfinavir mesylate at two doses as part of a combination regimen in HIV-infected, antiretroviral-naive patients. Design: Phase III, multicenter, double-blind, placebo-controlled trial.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::988847667d5af329b311b4b1d3086449
https://doi.org/10.1097/00002030-200110190-00009
https://doi.org/10.1097/00002030-200110190-00009
Publikováno v:
Drug Information Journal. 34:617-629
Statistical methods developed for survival analysis (time to event) were applied to treatments which are potent viral load suppressers in HIV-infected subjects. The methodology was applied to HIV-RNA levels obtained from the clinical study AG1343-511
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bcaf32f4bf034c8654b1065c50ab856c
https://doi.org/10.1177/009286150003400230
https://doi.org/10.1177/009286150003400230
Autor:
William G. Powderly, Barry D. Quart, Neil Clendeninn, George Yu, Michael S. Saag, Sharon Chapman
Publikováno v:
AIDS. 13:1873-1880
Background: Current potent antiretroviral therapy (using a protease inhibitor and two nucleoside reverse transcriptase inhibitors) produces a durable suppression of HIV replication in less than 75% of treated patients. Identification of predictors of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20964a8d94ab9c084bb894f03f457007
https://doi.org/10.1097/00002030-199910010-00009
https://doi.org/10.1097/00002030-199910010-00009
Autor:
Chris Higgs, Jo Monaghan, Graeme Moyle, William T. Prince, Sharon Chapman, Mark Nelson, Mike Youle, Neil Clendeninn
Publikováno v:
The Journal of Clinical Pharmacology. 38:736-743
The safety, antiretroviral activity, and pharmacokinetic profile of nelfinavir, a potent and specific inhibitor of human immunodeficiency virus (HIV) protease, were assessed in a small open-label phase I/II dose-ranging study in protease inhibitor-na
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e5484ef224cf432d058639227586167
https://doi.org/10.1002/j.1552-4604.1998.tb04814.x
https://doi.org/10.1002/j.1552-4604.1998.tb04814.x
Autor:
Geoffrey J. Yuen, Amy Hendricks, Margarita Duran, William J. Hoskins, Joanna Peterkin, Marcus A. Conant, Arlene Hurley, David D. Ho, Martin Markowitz, Sharon Chapman, Amy Patick, Rosemary Schluger, Neil Clendeninn
Publikováno v:
The Journal of Infectious Diseases. 177:1533-1540
A phase I/II dose-ranging open-label 28-day monotherapy study of the safety, pharmacokinetics, and antiviral activity of nelfinavir mesylate (Viracept), an inhibitor of human immunodeficiency virus (HIV)-1 protease, was done in 65 HIV-1 ‐ infected
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e70daabc0c8849d503b1a73ea80f80d6
https://doi.org/10.1086/515312
https://doi.org/10.1086/515312
Autor:
Paulina Essunger, Neil Clendeninn, Alan S. Perelson, Martin Markowitz, John E. Mittler, Geoffrey J. Yuen
Publikováno v:
Antimicrobial agents and chemotherapy. 45(5)
We calculated the relative efficacy of treatment, defined as the rate of decline of virus levels in plasma during treatment relative to the rate of decline during highly potent combination therapy, in human immunodeficiency virus type 1 (HIV-1) patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff356b69af36df9aae47e8db9f36488f
https://pubmed.ncbi.nlm.nih.gov/11302807
https://pubmed.ncbi.nlm.nih.gov/11302807
Autor:
Minaxi Jhawer, Lee Rosen, Janet Dancey, Howard Hochster, Solomon Hamburg, Margaret Tempero, Neil Clendeninn, Sridhar Mani
Publikováno v:
Investigational New Drugs; Feb2007, Vol. 25 Issue 1, p85-94, 10p